SPONSOR
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Total Trials
13
Recruiting
13
Phases
Phase 3, Phase 1, Phase 2, Phase 1, Phase 2
Conditions studied: Diffuse Large B-cell LymphomaSolid TumorNon-small Cell Lung Cancer (NSCLC)Recurrent or Metastatic Cervical CancerAdvanced Hepatocellular CarcinomaMalignant Tumors of AdultsAdvanced Renal Cell CarcinomaAdvanced Biliary Tract CancerLocally Advanced Rectal CancerAdvanced or Metastatic Non-small Cell Lung Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd. is a clinical research sponsor with 13 registered studies on ClinicalTrials.gov, of which 13 are actively recruiting participants. Research covers conditions including Diffuse Large B-cell Lymphoma, Solid Tumor, Non-small Cell Lung Cancer (NSCLC), Recurrent or Metastatic Cervical Cancer.
The trial portfolio spans Phase 3, Phase 1, Phase 2, Phase 1 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Suzhou Suncadia Biopharmaceuticals Co., Ltd.
How many clinical trials has Suzhou Suncadia Biopharmaceuticals Co., Ltd. sponsored?
ClinicalMetric currently tracks 13 clinical trials sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd., of which 13 are actively recruiting participants. These trials cover conditions including Diffuse Large B-cell Lymphoma, Solid Tumor, Non-small Cell Lung Cancer (NSCLC). Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Suzhou Suncadia Biopharmaceuticals Co., Ltd. research focus on?
Suzhou Suncadia Biopharmaceuticals Co., Ltd. clinical trials span Diffuse Large B-cell Lymphoma, Solid Tumor, Non-small Cell Lung Cancer (NSCLC), Recurrent or Metastatic Cervical Cancer, Advanced Hepatocellular Carcinoma, and additional conditions. The research pipeline includes Phase 3, Phase 1, Phase 2, Phase 1 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Suzhou Suncadia Biopharmaceuticals Co., Ltd. clinical trial?
To participate in a Suzhou Suncadia Biopharmaceuticals Co., Ltd. trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Suzhou Suncadia Biopharmaceuticals Co., Ltd. trials with current recruitment status updated daily.
Clinical Trials by Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NCT06929624 Phase 3
Recruiting
A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma
Diffuse Large B-cell Lymphoma
NCT07229638 Phase 1, Phase 2
Recruiting
A IB/II Phase Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors
Solid Tumor
NCT06754930 Phase 1, Phase 2
Recruiting
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC
Non-small Cell Lung Cancer (NSCLC)
NCT06859775 Phase 1, Phase 2
Recruiting
SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer
Recurrent or Metastatic Cervical Cancer
NCT06618664 Phase 3
Recruiting
A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab or Atezolizumab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma
Advanced Hepatocellular Carcinoma
NCT07068932 Phase 1
Recruiting
A Clinical Study of SHR-4506 Injection in Patients With Malignant Tumors
Malignant Tumors of Adults
NCT07275242 Phase 1
Recruiting
A Clinical Study of SHR-A1811(sc) Subcutaneous Injection in Patients With Solid Tumor
Solid Tumor
NCT07239596 Phase 1, Phase 2
Recruiting
Phase Ib/II Clinical Study of SHR-8068 Combined Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom
Advanced Renal Cell Carcinoma
NCT07676903 Phase 1
Recruiting
A Clinical Study of SHR-4685 on Safety, Tolerability and Pharmacokinetics in Participants With Solid Tumors
Solid Tumor
NCT07229625 Phase 3
Recruiting
A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)
Advanced Biliary Tract Cancer
NCT05300269 Phase 2
Recruiting
SHR-1701 in Combination With Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer
Locally Advanced Rectal Cancer
NCT07170995 Phase 3
Recruiting
Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer
Advanced or Metastatic Non-small Cell Lung Cancer
NCT07478302 Phase 1
Recruiting
A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma
Advanced Unresectable Hepatocellular Carcinoma
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology